Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raffit Hassan

Showing results (121-130 of 150) with videos related to

Pageof 15
Sort By:
Gastroenterology|March 11, 2014
A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of miceBridget P Keenan, Yvonne Saenger, Michel I Kafrouni, et al.
Cell Reports. Medicine|February 11, 2023
Genomic and transcriptomic analyses identify a prognostic gene signature and predict response to therapy in pleural and peritoneal mesotheliomaNishanth Ulhas Nair, Qun Jiang, Jun Stephen Wei, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 1, 2020
Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase ExpressionDaniel Rathkey, Manakamana Khanal, Junko Murai, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 13, 2009
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domainsCarmine Carpenito, Michael C Milone, Raffit Hassan, et al.
Cancer Medicine|October 8, 2022
Systemic immune changes accompany combination treatment with immunotoxin LMB-100 and nab-paclitaxelGuillaume Joe Pegna, Min-Jung Lee, Cody J Peer, et al.
American Journal of Industrial Medicine|November 20, 2019
Workshop summary: Potential usefulness and feasibility of a US National Mesothelioma RegistryKristin J Cummings, Michael J Becich, David J Blackley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2020
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid TumorsRaffit Hassan, George R Blumenschein, Kathleen N Moore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2019
Clinical Response of Live-Attenuated, <i>Listeria monocytogenes</i> Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural MesotheliomaRaffit Hassan, Evan Alley, Hedy Kindler, et al.
JAMA Oncology|January 4, 2019
Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor TrialRaffit Hassan, Anish Thomas, John J Nemunaitis, et al.
Cancer Immunity|December 20, 2007
Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelinRaffit Hassan, Wolfgang Ebel, Eric L Routhier, et al.
Pageof 15

Showing results (121-130 of 150) with videos related to

Sort By:
Pageof 15
Gastroenterology|March 11, 2014
A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of miceBridget P Keenan, Yvonne Saenger, Michel I Kafrouni, et al.
Cell Reports. Medicine|February 11, 2023
Genomic and transcriptomic analyses identify a prognostic gene signature and predict response to therapy in pleural and peritoneal mesotheliomaNishanth Ulhas Nair, Qun Jiang, Jun Stephen Wei, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 1, 2020
Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase ExpressionDaniel Rathkey, Manakamana Khanal, Junko Murai, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 13, 2009
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domainsCarmine Carpenito, Michael C Milone, Raffit Hassan, et al.
Cancer Medicine|October 8, 2022
Systemic immune changes accompany combination treatment with immunotoxin LMB-100 and nab-paclitaxelGuillaume Joe Pegna, Min-Jung Lee, Cody J Peer, et al.
American Journal of Industrial Medicine|November 20, 2019
Workshop summary: Potential usefulness and feasibility of a US National Mesothelioma RegistryKristin J Cummings, Michael J Becich, David J Blackley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2020
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid TumorsRaffit Hassan, George R Blumenschein, Kathleen N Moore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2019
Clinical Response of Live-Attenuated, <i>Listeria monocytogenes</i> Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural MesotheliomaRaffit Hassan, Evan Alley, Hedy Kindler, et al.
JAMA Oncology|January 4, 2019
Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor TrialRaffit Hassan, Anish Thomas, John J Nemunaitis, et al.
Cancer Immunity|December 20, 2007
Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelinRaffit Hassan, Wolfgang Ebel, Eric L Routhier, et al.
Pageof 15